pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,092 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1156Endpoints875BioPharma Dive339BioSpace293Fierce Biotech277onclive165raps104globenewswire health73fda recalls
therapy area
allOncology7359Rare Disease1827Cardiology1672Immunology1456Hematology1302Vaccines1173Pulmonology1084Psychiatry & CNS858
  • Lilly showcases Jaypirca combination data in CLL at EHA26, debuting results from Ajax acquisition
    Eli Lilly highlighted new blood‑cancer data at the European Hematology Association meeting in Stockholm. The company presented early clinical results for its Jaypirca therapy combined with the stan…
    Endpoints · 2mo agoNeutral↗ source
  • California law bans four harmful food additives, part of legislator Jesse Gabriel's push against ultra-processed foods
    California Assemblymember Jesse Gabriel has become a prominent figure in state food policy, championing measures aimed at reducing the health risks of ultra-processed foods. In 2023 he introduced…
    STAT · 2mo agoRegulatoryPositive↗ source
← prev
page 27 of 44
next →
67
fda medwatch60
fda press38
Ophthalmology491
Pain469
Endocrinology & Metabolism466
Infectious Disease437
  • 73-year-old woman begins medical residency, says she's all in
    In a recent First Opinion podcast, Dawn Zuidgeest-Craft, who is nearly 73, shared her decision to start a medical residency after completing medical school in her early seventies. The interview was…
    STAT · 2mo agoPositive↗ source
  • Merck's Welireg and Keytruda combo receives FDA approval for adjuvant kidney cancer therapy
    Merck announced that its combination of the oral VEGFR inhibitor Welireg and the immunotherapy Keytruda has been cleared by the U.S. Food and Drug Administration. The clearance applies to patients…
    Endpoints · 2mo agoApprovalPositive↗ source
  • GSK completes $10.6 billion acquisition of Nuvalent, the largest in its history
    GSK announced it has completed a $10.6 billion purchase of Nuvalent, marking the biggest deal the company has ever undertaken. The transaction was disclosed on Tuesday and values Nuvalent at $124…
    Endpoints · 2mo agoDealNeutral↗ source
  • Prometheus secures $12 billion to develop artificial general engineers as biotech deals surge
    Prometheus announced a $12 billion capital raise aimed at building what it calls “artificial general engineers,” a new class of AI tools for biopharma research and development. Nonprofit Blood Can…
    STAT · 2mo agoDealPositive↗ source
  • Enliven Therapeutics raises $400M as Jazz's Zepzelca misses confirmatory trial
    Enliven Therapeutics, a biotech based in Burlingame, California, announced that it priced a public offering of its common stock that raised about $400 million. The capital raise follows the compan…
    Endpoints · 2mo agoDealNeutral↗ source
  • Veteran researcher warns new OMB grant rule could politicize U.S. science
    David J. Skorton, president of the Association of American Medical Colleges, writes that after four decades in research he has never seen a threat to science like the new grantmaking rule being con…
    STAT · 2mo agoRegulatoryNegative↗ source
  • AstronauTx appoints Michelle Mellion as new chief medical officer
    STAT+ columnist Ed Silverman reports on the latest personnel moves in the pharmaceutical sector, a regular feature that tracks hires, promotions and departures. The most recent addition is Michell…
    STAT · 2mo agoPositive↗ source
  • Blood Cancer United acquires remaining supply of discontinued investigational drug Luvelta
    Blood Cancer United, a nonprofit focused on blood cancers, is purchasing the remaining inventory of Luvelta, an investigational cancer drug that has been discontinued. The acquisition aims to pres…
    STAT · 2mo agoNeutral↗ source
  • Chile releases new data on effectiveness of food warning labels
    Chile's health officials have released fresh data that assess how well the country's food warning label system works. The findings add to ongoing research about whether mandatory labels influence…
    STAT · 2mo agoNeutral↗ source
  • J&J reports positive Phase 2/3 results for Imaavy in rare autoimmune anemia, paving way for label expansion
    Johnson & Johnson announced that its drug Imaavy, already approved for myasthenia gravis, produced durable hemoglobin improvements in a Phase 2/3 trial for warm autoimmune hemolytic anemia, a rare…
    BioPharma Dive · 2mo agoPositive readoutPositive↗ source
  • Summit Therapeutics cancels $500 million secondary share offering citing market conditions
    Summit Therapeutics announced it would pull a planned $500 million secondary share sale just one day after the announcement, saying market conditions were unfavorable. The offering had been slated…
    BioPharma Dive · 2mo agoDealNegative↗ source
  • Enliven Therapeutics' early-stage study shows 48% major molecular response in CML patients
    A targeted therapy from Enliven Therapeutics, ELVN-001, produced major molecular responses in 48% of participants with chronic myeloid leukemia (CML) in a 24‑week, early‑stage trial. The study eval…
    STAT · 2mo agoPositive readoutPositive↗ source
  • Synthetic lethality hype may spark new wave of biotech mergers
    The piece highlights rising enthusiasm for synthetic lethality as a cancer‑treatment strategy, especially after recent data releases. In an early‑stage trial, Tango Therapeutics reported that pati…
    STAT · 2mo agoPositive↗ source
  • Abridge secures strategic investment from Eli Lilly and partners with Nvidia on AI foundation model
    Abridge, a health‑tech AI company, announced two new deals on Thursday in New York. Eli Lilly will make a strategic investment in Abridge, signaling pharma interest in AI scribes that document vis…
    STAT · 2mo agoDealPositive↗ source
  • Nonprofit Blood Cancer United purchases remaining Luvelta supplies to keep compassionate access for children
    Blood Cancer United, formerly the Leukemia & Lymphoma Society, announced it will purchase the remaining inventory of Luvelta, an investigational antibody‑drug conjugate that had been discontinued.…
    STAT · 2mo agoDealPositive↗ source
  • Study finds socioeconomic status drives brain development differences in 9- and 10-year-olds
    Researchers at Washington University School of Medicine examined brain MRI scans from almost 12,000 children who were nine or ten years old. The analysis showed that a child's socioeconomic backgr…
    STAT · 2mo agoNeutral↗ source
  • CDC report finds rise in alcohol use among pregnant women since 2020
    A new CDC analysis shows that the proportion of pregnant adults who reported drinking in the past month increased after 2020. The survey data indicate that about 15% of pregnant women reported cur…
    STAT · 2mo agoNegative↗ source
  • HHS gives measured response to alcohol risk study as health news roundup covers soda link, NIH debate, diabetes apology and DOJ lawsuit
    The Department of Health and Human Services issued a cautious reaction to a recent paper that examined the relationship between alcohol consumption and health risks, noting the need for further evi…
    STAT · 2mo agoNeutral↗ source
  • Open-access fees rise to $12,850 for NIH-funded study in Nature Medicine
    In 2025 a randomized clinical trial led by Elizabeth Selvin was published in Nature Medicine without any publication charge. The paper underwent peer review and editorial processing at no cost to t…
    STAT · 2mo agoNegative↗ source
  • Parabilis raises $670M in record-setting Nasdaq debut to fund cancer drug development
    Parabilis completed a $670 million initial public offering on the Nasdaq, establishing the largest biotech debut in the exchange’s history. The offering drew strong investor demand even as attenti…
    Endpoints · 2mo agoDealPositive↗ source
  • Parabilis raises record $670 million in biotech IPO, the largest for a venture-backed company
    Parabilis Medicines, a biotech focused on "undruggable" targets, completed an initial public offering that raised $670 million, the biggest amount ever for a venture-backed biotech. The company so…
    BioPharma Dive · 2mo agoDealPositive↗ source
  • Sanofi halts rare disease trial as Parabilis launches record biotech IPO amid European pricing debate
    Sanofi announced it is stopping a Phase 3 trial of its experimental drug riliprubart in a rare autoimmune disease after an interim analysis showed the treatment did not work. The pause adds to rec…
    STAT · 2mo agoNeutral↗ source
  • GSK to buy Nuvalent for $10.6B, gaining two lung-cancer drugs under FDA review
    GSK announced it will acquire Nuvalent, a biotech focused on lung cancer, in a transaction valued at about $10.6 billion. The deal gives GSK control of Nuvalent’s two experimental lung-cancer ther…
    Endpoints · 3mo agoDealPositive↗ source